F
Fritz H. Schröder
Researcher at Erasmus University Medical Center
Publications - 612
Citations - 41273
Fritz H. Schröder is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 98, co-authored 610 publications receiving 39254 citations. Previous affiliations of Fritz H. Schröder include Clinical Trial Service Unit & University of Oulu.
Papers
More filters
Journal ArticleDOI
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
Journal ArticleDOI
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L.J. Tammela,Marco Zappa,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Liisa Määttänen,Hans Lilja,Louis Denis,Franz Recker,Alvaro Paez,Chris H. Bangma,Sigrid Carlsson,Sigrid Carlsson,Donella Puliti,Arnauld Villers,Xavier Rebillard,Matti Hakama,Ulf-Håkan Stenman,Paula Kujala,Kimmo Taari,Gunnar Aus,Andreas R. Huber,Theo van der Kwast,Ron H.N. van Schaik,Harry J. de Koning,Sue Moss,Anssi Auvinen +29 more
TL;DR: In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.
Journal ArticleDOI
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,Alvaro Paez,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Sigrid Carlsson,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Paula Kujala,Bert G. Blijenberg,Ulf-Håkan Stenman,Andreas R. Huber,Kimmo Taari,Matti Hakama,Sue Moss,Harry J. de Koning,Anssi Auvinen +27 more
TL;DR: Analyses after 2 additional years of follow-up consolidated the previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.
Journal ArticleDOI
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.
Gerrit Draisma,Rob J. de Boer,Suzie J. Otto,Ingrid W. van der Cruijsen,Ronald A. M. Damhuis,Fritz H. Schröder,Harry J. de Koning +6 more
TL;DR: In this paper, the authors developed simulation models based on results of the Rotterdam section of the European Randomized Study of Prostate Cancer (ERSPC), which enrolled 42,376 men and in which 1498 cases of prostate cancer were identified.
Journal ArticleDOI
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
Otilia Dalesio,H. van Tinteren,Mike Clarke,Richard Peto,Fritz H. Schröder,I Dechering,V Evans,Jon Godwin,Brent A. Blumenstein,E. D. Crawford,Louis Denis,R Hall,Catherine Hill,P Iversen,W U Shipley,M. Soloway,Richard Sylvester,Collaborat Pct. +17 more
TL;DR: In advanced prostate cancer, addition of an antiandrogen to AS improved the 5-year survival by about 2% or 3% (depending on whether the analysis includes or excludes the cyproterone acetate trials), but the range of uncertainty as to the true size of this benefit runs from about 0% to about 5%.